A fourth event in the popular Horizons in Biomedical Series entitled 'The 'Nexxt' Big Thing in Inflammation' will be held on the evening of 16 February 2005 at the Glasgow Science Centre at Pacific Quay, Glasgow.

The event, which will focus on the role which inflammation and anti-inflammatory drugs play in rheumatoid arthritis and also in disorders of the smaller blood vessels, is organised by Nexxus, the West of Scotland Bioscience Network, and features a variety of speakers.

After a welcome from Professor Roger Sturrock, McLeod/ARC Professor of Rheumatology, University of Glasgow, the first speaker, Dr Navaad Sattar, Reader in Endocrinology and Metabolism, University of Glasgow and Honorary Consultant in Clinical Biochemistry, Glasgow Royal Infirmary will explore the contribution of low and high-grade inflammation to cardiovascular risk. #

Professor John Campbell Lockhart, Professor of Physiology, University of Paisley and Honorary Research Fellow, Department of Medicine, University of Glasgow will then discuss PAR-2 in arthritis.

Next, Professor Iain B McInnes, Professor of Experimental Medicine/Honorary Consultant Rheumatologist in the Centre for Rheumatic Diseases, University of Glasgow will consider inflammatory cytoklines in the therapeutic domain. Finally, Dr Martin Braddock, Senior Principal Scientist and Associate Director, AstraZeneca R&D, will look at future horizons in anti-inflammatory drug discovery. AstraZeneca is one of the world's leading pharmaceutical companies and focuses on providing new and effective prescription medicines that make a real difference for patients. Nexxus is funded by the European Regional Development Fund, the Scottish Enterprise Network, the University of Glasgow and Glasgow City Council.

For further information on the inflammation research capabilities in the West of Scotland, please see the Nexxus website Nexxus Website.

Media Relations Office (media@gla.ac.uk)

For more details contact Jan Clark, Marketing Communications Officer at Nexxus on 0141-330-1987

First published: 16 February 2005